

Amendment

Tandem CAR T cells targeting HER2 and IL13R α 2 mitigate tumor antigen escape

Meenakshi Hegde, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A. Navai, Amanda Wakefield, Kristen Fousek, Kevin Bielamowicz, Kevin K.H. Chow, Vita S. Brawley, Tiara T. Byrd, Simone Krebs, Stephen Gottschalk, Winfried S. Wels, Matthew L. Baker, Gianpietro Dotti, Maksim Mamonkin, Malcolm K. Brenner, Jordan S. Orange, and Nabil Ahmed

Original citation: *J Clin Invest*. 2016;126(8):3036–3052. <https://doi.org/10.1172/JCI83416>.

Citation for this amendment: *J Clin Invest*. 2021;131(13):e152477. <https://doi.org/10.1172/JCI152477>.

The Editors posted an Expression of Concern for this article following notification that two images in Figure 9D were subsequently published as distinct samples in another paper (1). An institutional review of the primary data supports that the images in the *JCI* article are correct and that no corrective action is required.

1. Bielamowicz K, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. *Neuro Oncol*. 2018;20(4):506–518.